Estazolam

Summary

Estazolam (CHEMBL285674) is an approved small-molecule anxiolytic drug (ATC N05CD04); indicated across 2 conditions including insomnia and sleep disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CD04
• Indications: 2 conditions
• Clinical trials: 6
• Chemistry: 294.74 Da · C16H11ClN4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL285674
Name	Estazolam
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3261
ChEBI	CHEBI:4858
ATC	N05CD04
Molecular formula	C16H11ClN4
Molecular weight	294.74
InChIKey	CDCHDCWJMGXXRH-UHFFFAOYSA-N

SMILES: C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4

IUPAC name: 8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine

ChEBI definition: A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia.

Pharmacological roles (ChEBI): anxiolytic drug, anticonvulsant, GABA modulator.

Also known as: ABBOTT-47631, Estazolam, Estazolam civ, Eurodin, NSC-290818, Prosom, estazolam, ESTAZOLAM, SID50113063, SID144206162

Patent coverage: 3,214 distinct patent families (12,284 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 12,258 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Kappa-type opioid receptor, 3’,5’-cyclic-AMP phosphodiesterase 4D, Gamma-aminobutyric acid receptor subunit alpha-1.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P62813	7.47	AC50	33.6	nM	CHEMBL_ACT_25130715
PDE4D	5	AC50	10000	nM	CHEMBL_ACT_25185449

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
insomnia	4	MONDO:0013600	EFO:0004698

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
sleep disorder	3	MONDO:0100081	EFO:0008568

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE4	3
PHASE3	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07306494	PHASE4	NOT_YET_RECRUITING	Compound Ciwujia Granules in the Treatment of Insomnia
NCT00956319	PHASE4	COMPLETED	A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients
NCT03997058	PHASE4	UNKNOWN	Observation on the Effect of Auricular Acupoint Pressing on Insomnia and Adverse Events in MHD
NCT06859190	PHASE3	RECRUITING	Efficacy of Auricular Pressure Beans with Electroacupuncture and Estazolam Treating Insomnia Caused by Cancer
NCT00347295	PHASE3	COMPLETED	Randomised, Double-blind Study to Investigate the Safety and Efficacy of Brotizolam in Insomnia Outpatients.
NCT06212934	Not specified	UNKNOWN	Chou’s Tiaoshen Acupoints for Short-term Insomnia.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).